Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Transitional Cell 16Urinary Bladder Neoplasms 14Carcinoma, Merkel Cell 10Neoplasm Metastasis 8Carcinoma, Renal Cell 8Breast Neoplasms 8Neoplasms 6Triple Negative Breast Neoplasms 5Melanoma 5Stomach Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Ovarian Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Urethral Neoplasms 3Ureteral Neoplasms 3Skin Neoplasms 3Prostatic Neoplasms 3Colorectal Neoplasms 3Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Neuroendocrine Tumors 2Head and Neck Neoplasms 2Endometrial Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Hepatocellular 2Uveal Melanoma 1Urothelial Cancer 1Turcot syndrome 1Thymoma 1

Interventions

Gemcitabine 15Cisplatin 15pembrolizumab 9Oxaliplatin 7durvalumab 5Leucovorin 5Fluorouracil 5130-nm albumin-bound paclitaxel 5Platinum 4Capecitabine 4Albumin-Bound Paclitaxel 41,2-diaminocyclohexaneplatinum II citrate 4fludarabine 3Trastuzumab 3Taxes 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Cyclophosphamide 3zanidatamab 2S 1 (combination) 2Paclitaxel 2Nivolumab 2Folfox protocol 2Docetaxel 2Biopsy 2tucatinib 1trifluridine tipiracil drug combination 1trastuzumab deruxtecan 1tivozanib 1pertuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gallbladder Neoplasms × avelumab × 1 year × Clear all
NCT04068194 2026-05-13

Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
103 enrolled
Gastrointestinal

Gallbladder Neoplasms, Neoplasm Metastasis, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡